glp-1 gip therapy alternatives 2025 Agonists Weight Loss Drugs Market Report, 2025-2030 Comparing GLP‑1 Drugs With Other
Description
Treatment duration is another point of divergence
When ANOVA indicated a significant difference among groups, these groups were compared by Dunnetts, Tukeys or Bonferronis post hoc test
MI and its consequent tissue damage leading to heart failure are mainly responsible for the fatality in patients with T2DM
Inhibition of dipeptidyl peptidase-4 impairs ventricular function and promotes cardiac fibrosis in high fat-fed diabetic mice
Doctors should increase doses only after confirming the patient's tolerance without major gastrointestinal effects [10]
Chemical analogues of GLP-1 are currently approved for the treatment of type 2 diabetes (T2D) and obesity 3,4
